JNS-101 is under development for the treatment of Friedreich’s ataxia. The drug candidate is a micronized formulation of pharmaceutical grade trans-resveratrol. The drug candidate is administered through oral route. It acts by targeting frataxin.
Friday, December 22, 2023
JNS-101 by Jupiter Neurosciences for Friedreich Ataxia: Likelihood of Approval
December 21, 2023. JNS-101 is under clinical development by Jupiter Neurosciences and currently in Phase II for Friedreich Ataxia. According to GlobalData, Phase II drugs for Friedreich Ataxia does not have sufficient historical data to build an indication benchmark PTSR for Phase II.
